Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 13/20 | 1.00 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenabasum SCHEMBL29872156 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056887 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL7056881 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL17414503 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL13035015 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL23202520 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL29362927 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| Lenabasum SCHEMBL6406468 | 1.00 | CNR2 (1.00) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL29611496 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 | |
| SCHEMBL14501182 | 0.99 | CNR2 (0.98) | CNR2CNR1GLRA1NR1I2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | claimed |
| EP-1879891-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-23 | — | — | EP | claimed |
| EP-1877410-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-16 | — | — | EP | claimed |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | claimed |
| WO-2006117316-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE US ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| WO-2006117315-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | SEIBERT KAREN (US) | 2004-09-23 | — | — | US | claimed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | PHARMACIA CORPORATION | 2003-10-23 | — | — | US | claimed |
| US-20030153801-A1 | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20230339880-A1 | COMPOSITIONS OF AJULEMIC ACID AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339880-A1 | COMPOSITIONS OF AJULEMIC ACID AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | WYLDER NATION FOUNDATION | 2023-06-15 | — | — | US | disclosed |
| EP-4153169-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | Wylder Nation Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | TAYLOR CHARLES PRICE (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030153801-A1 | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORPORATION | 2003-08-14 | — | — | US | disclosed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211163-A1 | Combination antiviral therapy | EIF2AK2, ZC3HAV1, VHL | CNR2 4135/4885CNR1 4096/4885GLRA1 4312/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CNR2 517/4885CNR1 1487/4885GLRA1 3532/4885 |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | CACNG2, GABRB2, CACNG4 | CNR2 57/4885CNR1 193/4885GLRA1 39/4885 |
| US-20230339880-A1 | COMPOSITIONS OF AJULEMIC ACID AND USES THEREOF | HMGCR, DHCR7, ALOX5 | CNR2 633/4885CNR1 283/4885GLRA1 1849/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CNR2 332/4885CNR1 1648/4885GLRA1 3715/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | CNR2 507/4885CNR1 1560/4885GLRA1 2692/4885 |
| US-20030199482-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | CNR2 540/4885CNR1 1196/4885GLRA1 1207/4885 |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | CNR2, CNR1, ICOS | CNR2 1/4885CNR1 2/4885GLRA1 3428/4885 |
| US-20040186154-A1 | Therapeutic combinations for cardiovascular and inflammatory indications | HMGCR, HMGB2, HMGB3 | CNR2 540/4885CNR1 1196/4885GLRA1 1207/4885 |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | GBA1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885GLRA1 1005/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | CNR2 1113/4885CNR1 1914/4885GLRA1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.